OBJECTIVES: To conduct a pharmacoeconomic analysis of the treatment of this disease by studying the costs of drugs used in the treatment of Itsenko-Cushing's disease(ICD).

METHODS: A comparative analysis of treatment with drugs in the international unpatented name "Cabergoline" used in the treatment of Itsenko-Cushing's disease was carried out by the method of "Cost minimization analysis".

RESULTS: Based on the information of the Republican Specialized Scientific and Practical Medical Center of Endocrinology named after academician Yo.Kh. Torakulov, the total costs of one patient for the treatment of Itsenko-Cushing's disease were calculated. During the study, 60 patients were examined for diagnosis and treatment costs. According to the results, 1,580,000 soums were spent to diagnose this disease at the center. According to the 2023 data of the State Register of Medicines, Medical Products and Medical Equipment registered in the Republic of Uzbekistan, 5 types of drugs containing Cabergoline have been registered. In the second stage of the research, we used the "Cost Minimization Analysis" based on the fact that the effectiveness of the drugs is the same.

CMA= (DC1 + IC1) - (DC2 + IC2)

Here: CMA - cost difference indicator;

DC1 and DC2- direct costs used in the first and second treatment methods;

IC1 and IC2- indirect costs used in the first and second treatment methods;

CONCLUSIONS: During the "Cost-minimization analysis" for the drugs used in the treatment of Itsenko-Cushing's disease, the direct costs of "Cabergolin" tablet 0.5 mg №24, Obnin chemical-pharmaceutical enterprise (Russia) in the first-method analysis of treatment costs - 1,220,000 soums, indirect costs - 1,580,000 soums, total 2,800,000 soums. In the second method, "Dostinex" tablet 0.5 mg №8, Pfizer Italia S.r.l. (Italy) treatment expenses amounted to 1,896,000 soums and 1,580,000 soums, a total of 3,476,000 soums. The difference in treatment methods was 676,000 soums.